By combining in vitro studies using BC cell lines and clinical data from human samples, Ding et al. found that PYCR1, but not PYCR2, is highly expressed in BCs independently of the specific subtype (ER+ vs. ER−), and positively correlates with tumor size, grade and invasiveness. Here, ESR1 is linked to breast cancer.